MassMutual Private Wealth & Trust’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.7K Hold
410
﹤0.01% 1207
2026
Q1
$8.7K Hold
410
﹤0.01% 1423
2025
Q4
$6.69K Hold
410
﹤0.01% 1559
2025
Q3
$4.79K Hold
410
﹤0.01% 1688
2025
Q2
$4.75K Buy
410
+398
+3,317% +$3.63K ﹤0.01% 1661
2025
Q1
$105 Buy
+12
New +$151 ﹤0.01% 2328
2024
Q4
Sell
-30
Closed -$677 2363
2024
Q3
$677 Sell
30
-41
-58% -$848 ﹤0.01% 1934
2024
Q2
$1.38K Buy
71
+41
+137% +$1.07K ﹤0.01% 1745
2024
Q1
$1.13K Sell
30
-1
-3% -$44 ﹤0.01% 1674
2023
Q4
$1.74K Buy
31
+2
+7% +$87 ﹤0.01% 1548
2023
Q3
$1.2K Buy
29
+19
+190% +$988 ﹤0.01% 1640
2023
Q2
$558 Hold
10
﹤0.01% 1757
2023
Q1
$558 Hold
10
﹤0.01% 1662
2022
Q4
$0 Buy
+10
New +$327 ﹤0.01% 1860
2022
Q3
Sell
-4
Closed 1820
2022
Q2
$0 Buy
+4
New +$208 ﹤0.01% 1718
2022
Q1
Sell
-19
Closed -$3K 1634
2021
Q4
$3K Buy
19
+4
+27% +$613 ﹤0.01% 1032
2021
Q3
$2K Hold
15
﹤0.01% 1094
2021
Q2
$3K Buy
+15
New +$2.71K ﹤0.01% 963

Other funds holding TXG

MassMutual Private Wealth & Trust's TXG Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its 10x Genomics (TXG) position steady in Q2 2026 at 410 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1207.

MassMutual Private Wealth & Trust first reported a position in TXG in Q2 2021 and has held it in 18 quarters since. 98 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • MassMutual Private Wealth & Trust held 410 shares of 10x Genomics worth $15.7K as of Q2 2026.
  • MassMutual Private Wealth & Trust left its 10x Genomics share count unchanged in Q2 2026.
  • 10x Genomics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1207 holding.
  • MassMutual Private Wealth & Trust first reported a position in 10x Genomics in Q2 2021 and has held it in 18 quarters since.
  • 98 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.